Regentis Biomaterials (RGNT) Payables (2024 - 2025)

Regentis Biomaterials (RGNT) reported Payables of $1.5 million for Q4 2025, down 14.14% year-over-year from $1.7 million in Q4 2024, and down 14.14% quarter-over-quarter from $1.7 million in Q4 2024.

Regentis Biomaterials (RGNT) Payables (2024 - 2025) Analysis & Trends

Regentis Biomaterials (RGNT) has 2 years of Payables data on file, last reported at $1.5 million in Q4 2025.

  • Payables for Q4 2025 came in at $1.5 million, down 14.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (down 14.14% YoY), and the FY2025 annual result was $1.5 million, down 14.14% from the prior year.
  • Payables retreated to $1.5 million in Q4 2025 per RGNT's latest filing, from $1.7 million in the prior quarter.
  • Over five years, Payables peaked at $1.7 million in Q4 2024 and troughed at $1.5 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Payables (Qtr)
1 Intuitive Surgical 148.09 Bn 143.69 Bn 1.83 Bn 332.90 Mn
2 Becton Dickinson 41.00 Bn 39.99 Bn 2.15 Bn 5.93 Bn
3 Medline 30.38 Bn 36.22 Bn 1.84 Bn 932.00 Mn
4 Resmed 28.22 Bn 26.56 Bn 890.98 Mn 533.23 Mn
5 West Pharmaceutical Services 23.72 Bn 23.19 Bn 296.40 Mn 252.30 Mn
6 Solventum 13.33 Bn 13.33 Bn 1.10 Bn 699.00 Mn
7 Cooper Companies 13.12 Bn 12.99 Bn 735.40 Mn 233.30 Mn
8 Align Technology 12.86 Bn 11.80 Bn 736.59 Mn 123.72 Mn
9 Baxter International 10.51 Bn 8.47 Bn 891.00 Mn 1.09 Bn
10 Regentis Biomaterials 3.72 Mn -3.66 Mn - 1.46 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.46 Mn
Dec 31, 2024 1.70 Mn